No evidence for genetic association between DARPP-32 (PP1R1B) polymorphisms and attention deficit hyperactivity disorder

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 147, Issue 3, 2008, Pages 339-342

  Laurin, Nancy ^a   Ickowicz, Abel ^b   Pathare, Tejaswee ^b   Malone, Molly ^b   Tannock, Rosemary ^b   Schachar, Russell ^b   Kennedy, James L ^c   Barr, Cathy L ^a,b,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

ADHD; DARPP 32; Dopamine signaling; Genetics; PPP1R1B; TDT

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE TRANSPORTER; PHOSPHOPROTEIN DARPP 32;

ALLELE; ARTICLE; ATTENTION DEFICIT DISORDER; DAT1 GENE; DOPAMINERGIC SYSTEM; DRD1 GENE; DRD4 GENE; DRD5 GENE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; IMPULSIVENESS; NEUROTRANSMISSION; PPP1R1B GENE; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ALLELES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; HUMANS; POLYMORPHISM, GENETIC;

ANIMALIA;

EID: 42149140621     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30604     Document Type: Article

References (35)

1. Albert KA, Hemmings HC Jr., Adamo AI, Potkin SG, Akbarian S, Sandman CA, Cotman CW, Bunney WE, Jr., Greengard P. 2002. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry 59(8):705-712.
2. Arnsten AF, Dudley AG. 2005. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav Brain Funct 1(1):2.
3. Baracskay KL, Haroutunian V, Meador-Woodruff JH. 2006. Dopamine receptor signaling molecules are altered in elderly schizophrenic cortex. Synapse 60(4):271-279.
4. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263-265.
5. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ. 1999. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402(6762):669-671.
6. Bobb AJ, Addington AM, Sidransky E, Gornick MC, Lerch JP, Greenstein DK, Clasen LS, Sharp WS, Inoff-Germain G, Wavrant-De Vrieze F. 2005. Support for association between ADHD and two candidate genes: NET1 and D RD1. Am J Med Genet Part B 134B(1):67-72.
7. Clayton D. 1999. A generalization of the transmission/disequilibrium test for uncertain-haplotype transmission. Am J Hum Genet 65(4):1170-1177.
8. Corvol JC, Studler JM, Schonn JS, Girault JA, Herve D. 2001. Galpha(olf) is necessary fcir coupling D1 and A2a receptors to adenylyl cyclase in the striatum. J Neurochem 76(5):1585-1588.
9. Dudbridge F. 2003. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25(2):115-121.
10. Faraone SV, Khan SA. 2006. Candidate gene studies of attention-deficit/ hyperactivity disorder. J Clin Psychiatry 67 (Suppl 8):13-20.
11. Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A, Cheramy A, O'Callaghan JP, Miller DB, Cole DG. 1998. DARPP-32: Regulator of the efficacy of dopaminergic neurotransmission. Science 281(5378):838-842.
12. Greengard P, Allen PB, Nairn AC. 1999. Beyond the dopamine receptor: The DARPP-32/protein phosphatase-1 cascade. Neuron 23(3):435-447.
13. Hemmings HC, Jr., Greengard P, Tung HY, Cohen P. 1984. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 310(5977):503-505.
14. Hiroi N, Fienberg AA, Haile CN, Alburges M, Hanson GR, Greengard P, Nestler EJ. 1999. Neuronal and behavioural abnormalities in striatal function in DARPP-32-mutant mice. Eur J Neurosci 11(3):1114-1118.
15. Horvath S, Xu X, Laird NM. 2001. The family based association test method: Strategies for studying general genotype - phenotype associations. Eur J Hum Genet 9(4):301-306.
16. Ickowicz A, Schachar R, Sugarman R, Chen S, Millette C, Cook L. 2006. The parent interview for child symptoms (PICS): A situation-specific clinicalresearch interview for attention deficit hyperactivity and related disorders. Can J Psychiatry 50:325-328.
17. Kirley A, Hawi Z, Daly G, McCarron M, Mullins C, Millar N, Waldman I, Fitzgerald M, Gill M. 2002. Dopaminergic system genes in ADHD: Toward a biological hypothesis. Neuropsychopharmacology 27(4):607-619.
18. Laurin N, Misener VL, Crosbie J, Ickowicz A, Pathare T, Roberts W, Malone M, Tannock R, Schachar R, Kennedy JL. 2005. Association of the calcyon gene (DRD1IP) with attention deficit/hyperactivity disorder. Mol Psychiatry 10(12):1117-1125.
19. Li CH, Liao HM, Hung TW, Chen CH. 2006. Mutation analysis of DARPP-32 as a candidate gene for schizophrenia. Schizophr Res 87(1-3):1-5.
20. Luca P, Laurin N, Misener VL, Wigg KG, Anderson B, Cate-Carter T, Tannock R, Humphries T, Lovett MW, Barr CL. 2007. Association of the dopamine receptor D1 gene, DRD1, with inattention symptoms in families selected for reading problems. Mol Psychiatry 12(8):776-785.
21. Miller SA, Dykes DD, Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215.
22. Misener VL, Schachar R, Ickowicz A, Malone M, Roberts W, Tannock R, Kennedy JL, Pathare T, Barr CL. 2004. Replication test for association of the IL-I receptor antagonist gene, IL1RN, with attention-deficit/hyperactivity disorder. Neuropsychobiology 50(3):231-234.
23. Nally RE, McNamara FN, Clifford JJ, Kinsella A, Tighe O, Croke DT, Fienberg AA, Greengard P, Waddington JL. 2003. Topographical assessment of etiological and dopamine receptor agonist-induced behavioral phenotype in mutants with congenic DARPP-32 'Knockout'. Neuropsychopharmacology 28(12):2055-2063.
24. Ogden CA, Rich ME, Schork NJ, Paulus MP, Geyer MA, Lohr JB, Kuczenski R, Niculescu AB. 2004. Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: An expanded convergent functional genomics approach. Mol Psychiatry 9(11):1007-1029.
25. Palmer AA, Verbitsky M, Suresh R, Kamens HM, Reed CL, Li N, Burkhart-Kasch S, McKinnon CS, Belknap JK, Gilliam TC. 2005. Gene expression differences in mice divergently selected for methamphetamine sensitivity. Mamm Genome 16(5):291-305.
26. Quist JF, Barr CL, Schachar R, Roberts W, Malone M, Tannock R, Basile VS, Beitchman J, Kennedy JL. 2000. Evidence for the serotonin HTR2A receptor gene as a susceptibility factor in attention deficit hyperactivity disorder (ADHD). Mol Psychiatry 5(5):537-541.
27. Seeman P, Madras BK. 1998. Anti-hyperactivity medication: Methylphenidate and amphetamine. Mol Psychiatry 3(5):386-396.
28. Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P. 2004. DARPP-32: An integrator of neurotransmission. Annu Rev Pharmacol Toxicol 44:269-296.
29. Svenningsson P, Nairn AC, Greengard P. 2005. DARPP-32 mediates the actions of multiple drugs of abuse. Aaps J 7(2):E353-E360.
30. Tannock R, Hum M, Masellis M, Humphries T, Schachar R. 2002. Teacher telephone interview for children's academic performance, attention, behavior and learning: DSM-IV Version (TTI-IV). Toronto Canada: The Hospital for Sick Children, Unpublished Document.
31. Thapar A, O'Donovan M, Owen MJ. 2005. The genetics of attention deficit hyperactivity disorder. Hum Mol Genet 14 (Spec No. 2):R275-R282.
32. The International HapMap Consortium. 2003. The International HapMap Project. Nature 426(6968):789-796.
33. Viggiano D, Ruocco LA, Sadile AG. 2003. Dopamine phenotype and behaviour in animal models: In relation to attention deficit hyperactivity disorder. Neurosci Biobehav Rev 27(7):623-637.
34. Wilens TE. 2006. Mechanism of action of agents used in attention-deficit/hyperactivity disorder. J Clin Psychiatry 67 (Suppl 8):32-38.
35. Zhuang X, Belluscio L, Hen R. 2000. G(olf)alpha mediates dopamine D1 receptor signaling. J Neurosci 20(16):RC91.